Director/PDMR Shareholding

Amphion Innovations plc

 ("Amphion" or "the Company")

(LSE: AMP)

Transfer of Shares

Amphion Innovations plc (the "Company") (LSE: AMP), the developer of medical and technology businesses, announces that it has received notification that on 19 January 2015 Richard Morgan, CEO of the Company, transferred 2,000,000 ordinary shares to his adult daughter for nil consideration. Following this transfer, Richard Morgan's beneficial interest in the Company is 23,642,499 ordinary shares representing 15.94% of the total voting rights in the Company.

For further information please contact:

Amphion Innovations plcCharlie Morgan+1 212 210 6224

Yellow Jersey PR Dominic Barretto / Fiona Walker+44 7768 537 739

Plumtree Capital Limited (Financial Advisor)

Stephen Austin

London: +44 207 183 5860

New York: +1 646 652 0799

Panmure Gordon Limited (Nominated Advisor and Broker)Freddy Crossley / Fred Walsh / Duncan Monteith (Corporate Finance)Charlie Leigh-Pemberton (Corporate Broking)+44 020 7886 2500

About Amphion Innovations plc

Amphion Innovations is a developer of medical, life science and technology businesses.

We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.

On the web: www.amphionplc.com